ERBB2 and gastric cancer: Notably, a documented case of HER2-positive advanced gastric cancer achieved a progression-free survival (PFS) of 17 months with second-line inetetamab plus chemotherapy—substantially exceeding the historical median PFS of 3–4 months for conventional second-line regimens (9, 12).